AMGEN INC (AMGN)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$12,038.0M
Cash & Equivalents
$2,189.0M
Quarterly Burn Rate
$196,125M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (16 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
RITUXIMAB-ARRX
RIABNI |
APPROVED | Abdominal Aortic Aneurysm, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Active Refractory Rheumatoid Arthritis, Active Systemic Lupus Erythematosus, Acute Anterior Uveitis (AAU), Acute Coronary Syndrome, Acute Leukemia, Acute Leukemia (Category), Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Lymphoma, Acute Metabolic Effects of Evolocumab and Atorvastatin, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute-graft-versus-host Disease, Adalimumab, Adenocarcinoma of the Distal Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Proximal Stomach, Adenocarcinomas of the Gastroesophageal Junction, Adenoma, Pleomorphic, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Adult Onset Rheumatoid Arthritis, Advanced Breast Cancer |
|
EVOLOCUMAB
REPATHA |
APPROVED | — |
|
APREMILAST
OTEZLA |
APPROVED | Atrophic Vaginitis Due to Menopause, Chronic Myeloid Leukemia, Common Warts, Epithelial Ovarian Cancer, Fasting, Gastrointestinal Stromal Tumor, Glaucoma, Open-Angle, Healthy Postmenopausal Women, Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases, Hepatitis B, HIV Infections, Hypogonadotropic Hypogonadism, Ocular Hypertension, Open-angle Glaucoma, Osteoarthritis, Pain, Parkinson Disease, Primary Hypogonadism, Psoriasis, Rheumatoid Arthritis, Schizophrenia, Seasonal Allergic Rhinitis, Uncomplicated Urinary Tract Infections, Urinary Tract Infections |
|
USTEKINUMAB-AUUB
WEZLANA |
APPROVED | — |
|
AFLIBERCEPT-AYYH
PAVBLU |
APPROVED | — |
|
ECULIZUMAB-AEEB
BKEMV |
APPROVED | — |
|
TARLATAMAB-DLLE
IMDELLTRA |
APPROVED | — |
|
ADALIMUMAB-ATTO
AMJEVITA |
APPROVED | — |
|
BEVACIZUMAB-AWWB
MVASI |
APPROVED | — |
|
ROMOSOZUMAB-AQQG
EVENITY |
APPROVED | — |
|
SOTORASIB
LUMAKRAS |
APPROVED | — |
|
TRASTUZUMAB-ANNS
KANJINTI |
APPROVED | — |
|
ERENUMAB-AOOE
AIMOVIG |
APPROVED | — |
|
INFLIXIMAB-AXXQ
AVSOLA |
APPROVED | — |
|
IVABRADINE HYDROCHLORIDE
CORLANOR |
NDA | — |
|
IVABRADINE
CORLANOR |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT01277419 | German Spondyloarthritis Inception Cohort | OTHER | Recruiting | 1,000 |
| NCT02009345 | Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada | OTHER | Recruiting | 6,000 |
| NCT07013578 | TIDHI Mental Health in IBD Patients Study | OTHER | Recruiting | 100 |
| NCT02925234 | The Drug Rediscovery Protocol (DRUP Trial) | PHASE2 | Recruiting | 1,550 |
| NCT03289299 | Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant | PHASE2 | Active Not Recruiting | 87 |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311... | PHASE1 | Recruiting | 380 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.